PCSK9 and Cirrhosis: Third, PCSK9inhibitors have been found to be safe alternatives in DILI, pregnancy andlactation, decompensated cirrhosis, dialysis, and coadministration with anti-HCVand immunosuppressive drugs in current studies [16, 17, 53, 81, 113, 124].Investigations of the application of PCSK9 inhibitors in these conditions arestill in the preliminary stages, so large clinical trials are somewhat limited todate.